In a clinical case study, a patient with an EGFRvIII mt recurrent GBM was reported to show longer progression-free survival after treatment with afatinib and protracted TMZ.41 It is thus likely that there will be a benefit with afatinib for selected patient cohorts with EGFR-mutant status. The gene discussed is EGFR; the disease is glioblastoma.